000 a
999 _c11468
_d11468
003 OSt
005 20200921144936.0
008 200921b xxu||||| |||| 00| 0 eng d
040 _aAIKTC-KRRC
_cAIKTC-KRRC
100 _99607
_aSingh, Sanjay Kumar
245 _aInvestigation of hub genes and their nonsynonymous single nucleotide polymorphism analysis in Plasmodium falciparum for designing therapeutic methodologies using next‑generation sequencing approach
250 _aVol.51(6), Nov-Dec
260 _aMumbai
_bWolter Kluwer
_c2019
300 _a389-399p.
520 _aBACKGROUND: Incidences of resistance to current drugs by Plasmodium is increasing, hence, it is necessary to investigate and explore new drug targets to combat malarial disease.OBJECTIVE: Analysis of the transcriptome sequence information to characterize hub genes and their nonsynonymous single nucleotide polymorphisms (nsSNPs) to derive therapeutic objectives for Plasmodium falciparum.MATERIALS AND METHODS: Differentially expressed genes between Ring and other stages of P. falciparum were identified using Cufflinks tool. Using DAVID and KAAS programs, the gene ontology and pathway analysis were performed. The networks of protein‑protein interaction (PPI) were developed by Search Tool for the Retrieval of Interacting Genes/Proteins and Cytoscape, and the node degree in the network was calculated by using Network Analyzer, and MCODE plugins of Cytoscape. SIFT, PROVEAN, and PredictSNP programs were used to study the genetic variations, which affect protein functions.RESULTS: Alist of 4196 nonredundant genes was used for functional annotation cluster analysis, and 8 significant hub genes have been picked from the PPI network using MCODE plugins of Cytoscape. Various nsSNPs were identified in these 8 hub genes and were investigated both for its native and mutant stage for solvent accessibility and alteration in secondary structure protein residues.CONCLUSION: Hub genes identified in this study serve as potential targets to develop therapy to suppress the pathogenic action of P.falciprum through experimental techniques
650 0 _94774
_aPHARMACOLOGY
700 _912564
_aReddy, Sudhakara M.
773 0 _x0253-7613
_dAndheri - Mumbai Wolters Kluwer India Private Limited
_tIndian Journal of Pharmacology
856 _uhttp://www.ijp-online.com/temp/IndianJPharmacol516389-3328048_091440.pdf
_yClick here
942 _2ddc
_cAR